

Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center
(Rm. 1503), Silver Spring, MD
September 12, 2013

DRAFT MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Caleb Briggs, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs
Center for Drug Evaluation and Research

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Deborah K. Armstrong, MD

Associate Professor of Oncology
The Sidney Kimmel Comprehensive Cancer
Center at Johns Hopkins
The Johns Hopkins University School of
Medicine
Baltimore, Maryland

Frank Balis, MD

The Louis and Amelia Canuso Family Endowed
Chair for Clinical Research in Oncology
The Children's Hospital of Philadelphia
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

Aman U. Buzdar, MD

Vice President Clinical Research and Interim
Professor of Medicine
MD Anderson Cancer Center
Dept. of Breast Medical Oncology
Houston, Texas

Bernard F. Cole, PhD

Professor, Department of Mathematics and
Statistics
University of Vermont
Burlington, Vermont

Louis F. Diehl, MD

Professor of Medicine
Duke University Medical Center
Durham, North Carolina

Tito Fojo, MD, PhD

Program Director, Medical Oncology
National Cancer Institute
Bethesda, Maryland

James Liebmann, MD

Assistant Professor of Medicine
Department of Medicine
University of Massachusetts
Worcester, Massachusetts

Michael Menefee, MD

Assistant Professor
Division of Hematology and Oncology
Mayo Clinic
Jacksonville, Florida

Mikael Sekeres, MD, MS

(Chairperson)
Associate Professor of Medicine
Staff, Cleveland Clinic Taussig Cancer Institute
Department of Hematologic Oncology and
Blood Disorders
Cleveland, Ohio

David Steensma, MD

Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
September 12, 2013

DRAFT MEETING ROSTER (cont.)

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting) (cont.)

Jane Zones, PhD

(Consumer Representative)

Medical Sociologist (retired)

Breast Cancer Action

National Women's Health Network

San Francisco, California

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBER (Non-Voting)

Howard Fingert, MD, FACP

(Industry Representative)

Senior Medical Director, Clinical Intelligence

Millennium, the Takeda Oncology Company

Cambridge, Massachusetts

TEMPORARY MEMBERS (Voting)

Brent Logan, PhD

Professor of Biostatistics

Division of Biostatistics

Medical College of Wisconsin

Milwaukee, Wisconsin

Gary Lyman, MD, MPH

Professor of Medicine

Director, Comparative Effectiveness and
Outcomes Research

Duke University School of Medicine

and the Duke Comprehensive Cancer Center

Durham, North Carolina

Debra Madden

(Patient Representative)

Newtown, Connecticut

Food and Drug Administration
Center for Drug Evaluation and Research
Oncologic Drugs Advisory Committee Meeting
September 12, 2013

DRAFT MEETING ROSTER (cont.)

FDA PARTICIPANTS (Non-Voting)

Richard Pazdur, MD

Director
Office of Hematology & Oncology Products
(OHOP),
Office of New Drugs (OND), CDER, FDA

Anthony Murgo, MD

Acting Director
Division of Oncology Products 1 (DOP1),
OHOP, OND, CDER, FDA

Patricia Cortazar, MD

Medical Team Leader,
Breast/Gynecologic Cancer Team
DOP1, OHOP, OND, CDER, FDA

Laleh Amiri-Kordestani, MD

Medical Officer
Breast/Gynecologic Cancer Team
DOP1, OHOP, OND, CDER, FDA

Suparna Wedam, MD

Medical Officer
Breast/Gynecologic Cancer Team
DOP1, OHOP, OND, CDER, FDA